Benzimidazole-based derivatives as privileged scaffold developed for the treatment of the RSV infection: a computational study exploring the potency and cytotoxicity profiles

Respiratory syncytial virus (RSV) has been identified as a main cause of hospitalisation in infants and children. To date, the current therapeutic arsenal is limited to ribavirin and palivizumab with variable efficacy. In this work, starting from a number of in-house series of previously described a...

Descripción completa

Detalles Bibliográficos
Autores principales: Cichero, Elena, Tonelli, Michele, Novelli, Federica, Tasso, Bruno, Delogu, Ilenia, Loddo, Roberta, Bruno, Olga, Fossa, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021036/
https://www.ncbi.nlm.nih.gov/pubmed/28276287
http://dx.doi.org/10.1080/14756366.2016.1256881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021036/
https://www.ncbi.nlm.nih.gov/pubmed/28276287
http://dx.doi.org/10.1080/14756366.2016.1256881

Ejemplares similares